U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Air Canada Express Plane Collides with Ground Vehicle at LaGuardia Airport 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Uncertainty and Japan Inflation Data 
Oil Prices Rebound as Iran Denies U.S. Talks, Middle East Tensions Persist 
Sanofi will be acquiring mRNA developer, Translate Bio, and this was revealed on Monday, Aug. 4. The French pharmaceutical company headquartered in Paris was reported to have offered to buy the US-based company after experiencing setbacks in its attempt to produce its own brand of COVID-19 vaccine.
As per CNBC, Sanofi will purchase all the available shares of the Massachusetts-headquartered mRNA therapeutics company at $38.00 per share. The total equity value is around $3.2 billion, and it will be paid in cash.
An insider who cannot be identified because of the confidentiality of the deal shared that Translate Bio’s board will hold a meeting to discuss the offer. Another source revealed that Sanofi’s executive directors also convened last Sunday to talk about the potential acquisition.
At any rate, it was said that the boards of the two companies gave their approval for the deal. Translate Bio’s chief executive officer, and the firm’s largest shareholder are reportedly backing the takeover offer by Sanofi, and this was confirmed through a joint statement.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Sanofi’s CEO, Paul Hudson, said in a press release. “A fully owned platform allows us to develop additional opportunities in the fast-evolving mRNA space and we will also be able to accelerate our existing partnered programs already under development.”
Hudson added that with Translate Bio, aside from vaccines, Sanofi’s goal is to unravel the potential of messenger ribonucleic acid (mRNA) in other medical fields, including immunology, oncology, and rare diseases.
Prior to this recent acquisition, Sanofi and Translate Bio have actually been working together since 2018, and last year, they teamed up to develop an mRNA-based vaccine for COVID-19. In the third quarter of this year, they are expecting to get provisional results of their Phase I/II clinical trial.
Meanwhile, Reuters reported that shares of Sanofi went up by more than 70% to over $50 in extended trading. The financial terms of the French firm’s offer were not disclosed at this time, and Translate Bio's market value has also soared to around $2.2 billion at the close on Monday.
